Company intelligence / Profile preview
Andante Biologics, Inc.
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
Overview
The company focused on developing platform immunotherapies for chronic stress-related diseases. There are no public reports of clinical trial results or advanced-stage programs. The company has ceased operations as of August 2024.
- Therapeutic areas
- Psychiatry
- Modalities
- Immunotherapies (platform immunotherapies)possible CNS gene therapy focus
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Andante Biologics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Andante Biologics, Inc..